What is the difference between Cerluten and Foxo4-DRI?

Cerluten: CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration. Foxo4-DRI: D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

Is Foxo4-DRI FDA approved?

Foxo4-DRI is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cerluten administered in research settings?

In research settings, Cerluten is typically administered via the oral or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is Foxo4-DRI administered in research settings?

In research settings, Foxo4-DRI is typically administered via the intravenous or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cerluten vs Foxo4-DRI

Peptide Comparison

Cerluten vs Foxo4-DRI

Name: Cerluten vs Foxo4-DRI — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

Cerluten

brain peptide bioregulator

LongevityResearch Only

1 providers listed

Full Cerluten profile →

Foxo4-DRI

Foxo4-D-Retro-Inverso

LongevityNot EvaluatedResearch Only

Half-life: Unknown

14 providers listed

Full Foxo4-DRI profile →

Bottom line

Foxo4-DRI is carried by more providers on PeptideBase (14 vs 1); otherwise the two are closely matched on the measures we track.

Quick Verdict

Cerluten

Foxo4-DRI

Which One Should You Choose?

Your goal	Better option
Oral administration option	Cerluten
More provider options (1 vs 14)	Foxo4-DRI

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cerluten

Foxo4-DRI

Mechanism Family

Longevity & Cellular

Half-life

—

Unknown

FDA Status

unknown

not evaluated

Admin Routes

oral, subcutaneous

intravenous, subcutaneous

Availability

Research Only

Providers

1 listed

14 listed

Avail. Notes

—

Senolytic D-retro-inverso Foxo4 peptide (de Keizer lab, Netherlands). Eliminates p21-positive senescent cells. No FDA approval, no IND or NDA. Novel research compound only.

Research Evidence

Cerluten

Review · 2 key studies · most recent 2022

Foxo4-DRI

Review · 3 key studies · most recent 2026

Research Citations

Cerluten

Review2022 · International Journal of Molecular Sciences

Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

Foxo4-DRI

Animal2021 · EBioMedicine

Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-…

Animal2017 · Cell

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Review2026 · Naunyn Schmiedebergs Arch Pharmacol

Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigat…

About Cerluten

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Research Areas

neuroprotectioncognitive supportmemoryanti-aginglongevity

About Foxo4-DRI

D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

Research Areas

senescent cell clearancetissue rejuvenationhealthspan extensionsenolytic

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cerluten

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Foxo4-DRI

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

Cerluten

Not enough vendor pricing yet.

Foxo4-DRI

$22.00/mg

$10.23 – $24.50 range

17 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Cerluten

1 listed

Browse directory →

Providers offering

Foxo4-DRI

14 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cerluten vs Foxo4-DRI — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/cerluten/foxo4-dri

https://peptidebase.io/peptides/compare/cerluten/foxo4-dri Methodology License Download JSON Download CSV